Vertex Pharmaceuticals Incorporated (VRTX) Competitors & Peers
The 5 companies closest to Vertex Pharmaceuticals Incorporated on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| REGN | Peer | $808.05 | P/E 19.4RSI 83Cap 83.2 B |
| ARGX | Peer | $866.11 | P/E 33.0RSI 49Cap 54.2 B |
| RVMD | Peer | $206.97 | RSI 68Cap 44.4 B |
| CSLLY | Peer | $23.77 | P/E 15.2RSI 68Cap 45.5 B |
| CMXHF | Peer | $93.67 | P/E 14.9RSI 70Cap 44.9 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- CRSPPartner
CRISPR + Vertex co-developed Casgevy (exa-cel) for sickle cell + beta thalassemia.
Model-inferred, unverified — treat as a lead, not evidence - RPRXSupplier
Royalty Pharma owns cystic fibrosis franchise (Trikafta) royalty from Vertex.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is one of Vertex's primary wholesale distributors for its cystic fibrosis medicines (Trikafta/Kaftrio) in the US.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Vertex and AbbVie compete in pain management — Vertex's Journavx (suzetrigine, Nav1.8 inhibitor) vs AbbVie's pipeline pain assets.
Model-inferred, unverified — treat as a lead, not evidence - GILDCompetitor
CF + virology overlap historically.
Model-inferred, unverified — treat as a lead, not evidence